Interest in α-emitters for radiotherapeutic applications is on the rise. However, the number of options for α-emitters with midterm industrial availability remains limited. With almost an ideal profile, is 212Pb really happening?

Find out more about the promise and challenges faced by lead-212 in the recent editorial published in the Nuclear medicine Journal (JNM) by Richard Zimmermann.

Read the editorial on the JNM website >>